# US 2015/0104870 A1 · Neuronal differentiation promoter

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104870 A1
- Document ID: US20150104870A1
- Status: Published application
- Kind: A1
- Application number: 14/397,376
- Filed: 2013-04-26
- Published: 2015-04-16
- Earliest claimed: 2012-04-27
- Assignees: Keio University
- Applicants: Keio University
- Inventors: Hayato Kaneda; Hideyuki Okano; Takuya Shimazaki
- Web page: https://patentgrep.com/patent/US20150104870A1

## CPC

- C12N 5/0623: {Stem cells}
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 35/30: Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 5/0619: {Neurons}
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12Y 207/11024: Mitogen-activated protein kinase (2.7.11.24), i.e. MAPK or MAPK2 or c-Jun N-terminal kinase
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/141: MicroRNAs, miRNAs
- C12N 2310/531: Stem-loop; Hairpin
- C12N 2501/65: MicroRNA
- C12N 2501/727: Kinases (EC 2.7.)
- C12N 2501/999: Small molecules not provided for elsewhere
- C12N 2506/08: from cells of the nervous system
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

The present invention provides an agent for promoting neuronal differentiation of neural stem cells, which contains a p38 inhibitor. In addition, the present invention provides a method of promoting neuronal differentiation of neural stem cells, which includes cultivating neural stem cells in the presence of a p38 inhibitor. Neural stem cells are gliogenic or neurogenic. The p38 inhibitor is a nucleic acid which hybridizes to DNA or mRNA encoding p38 under physiological conditions, thereby inhibiting the transcription and/or translation thereof, an expression vector of the nucleic acid, a low molecular p38 inhibitor and the like.

## Claims

### Claim 1

An agent for promoting neuronal differentiation of neural stem cells, comprising a p38 inhibitor.

### Claim 2 (depends on 1)

The agent according to claim 1, wherein the neural stem cell is gliogenic.

### Claim 3 (depends on 1)

The agent according to claim 1, wherein the neural stem cell is neurogenic.

### Claim 4 (depends on 1)

The agent according to claim 1, wherein the p38 inhibitor is a nucleic acid which hybridizes, under physiological conditions, to a DNA or mRNA encoding p38, thereby inhibiting the transcription and/or translation thereof, an expression vector of the nucleic acid, or a low molecular p38 inhibitor.

### Claim 5 (depends on 4)

The agent according to claim 4, wherein the nucleic acid is an siRNA, miRNA or a precursor thereof, or an antisense nucleic acid targeting p38.

### Claim 6 (depends on 5)

The agent according to claim 5, wherein the nucleic acid is miR-17, miR-106a, miR-106b, or a precursor of said miRNAs.

### Claim 7 (depends on 4)

The agent according to claim 4, wherein the p38 inhibitor is SB203580.

### Claim 8

A method of promoting neuronal differentiation of neural stem cells, comprising cultivating neural stem cells in the presence of a p38 inhibitor.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the neural stem cells are gliogenic.

### Claim 10 (depends on 8)

The method according to claim 8, wherein the neural stem cells are neurogenic.

### Claim 11 (depends on 8)

The method according to claim 8, wherein the p38 inhibitor is a nucleic acid which hybridizes, under physiological conditions, to a DNA or mRNA encoding p38, thereby inhibiting the transcription and/or translation thereof, an expression vector of the nucleic acid, or a low molecular p38 inhibitor.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the nucleic acid is an siRNA, miRNA or a precursor thereof, or an antisense nucleic acid targeting p38.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the nucleic acid is miR-17, miR-106a, miR-106b, or a precursor of said miRNAs.

### Claim 14 (depends on 11)

The method according to claim 11, wherein the p38 inhibitor is SB203580.

### Claim 15

A method of converting a gliogenic neural stem cell to a neurogenic neural stem cell, comprising cultivating a gliogenic neural stem cell in the presence of a p38 inhibitor.

### Claim at position 16

16-20. (canceled)

### Claim 21 (depends on 15)

The method according to claim 15, wherein the p38 inhibitor is a nucleic acid which hybridizes, under physiological conditions, to a DNA or mRNA encoding p38, thereby inhibiting the transcription and/or translation thereof, an expression vector of the nucleic acid, or a low molecular p38 inhibitor.

### Claim 22 (depends on 21)

The method according to claim 21, wherein the nucleic acid is an siRNA, miRNA or a precursor thereof, or an antisense nucleic acid targeting p38.

### Claim 23 (depends on 22)

The method according to claim 22, wherein the nucleic acid is miR-17, miR-106a, miR-106b, or a precursor of said miRNAs.

### Claim 24 (depends on 21)

The method according to claim 21, wherein the p38 inhibitor is SB203580.
